KNE.V - Kane Biotech Inc.
| Previous Close | 0.1100 |
| Open | 0.1050 |
| Bid | 0.0950 x 0 |
| Ask | 0.1050 x 0 |
| Day's Range | 0.1000 - 0.1050 |
| 52 Week Range | 0.0800 - 0.1500 |
| Volume | |
| Avg. Volume | 56,080 |
| Market Cap | 12.485M |
| Beta (5Y Monthly) | 0.14 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.0300 |
| Earnings Date | Aug 23, 2023 - Aug 28, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
GlobeNewswireKane Biotech Announces First Quarter 2023 Financial Results
WINNIPEG, Manitoba, May 25, 2023 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (the “Company” or “Kane Biotech”), a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms, today announced its first quarter 2023 financial results. First Quarter Financial Highlights: Total revenue for the three months ended March 31, 2023, was $677,617, an increase of 20% compared to $565,433 in the
GlobeNewswireKane Biotech Announces FDA 510(k) Clearance for its coactiv+™ Antimicrobial Wound Gel
Kane’s first FDA cleared medical device aims to disrupt global wound care hydrogel market coactiv+™ Antimicrobial Wound Gel Receives FDA Clearance coactiv+™ Antimicrobial Wound Gel is a premium hydrogel that provides scientifically-proven efficacy for wound healing in an easy-to-use thermo-reversible gel, all within Medicare and private payor allowable. WINNIPEG, Manitoba, May 25, 2023 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE OTCQB:KNBIF) (the “Company” or “Kane Biotech”) announces that
- GlobeNewswire
Kane Biotech to Release First Quarter 2023 Financial Results on May 25, 2023 – Conference Call to Follow
WINNIPEG, Manitoba, May 18, 2023 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (the “Company” or “Kane Biotech”), a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms, will announce its first quarter 2023 financial results after market close on Thursday, May 25, 2023. Kane Biotech management will host a conference call at 4:30 p.m. ET to review the financial results and discuss
- GlobeNewswire
Kane Biotech Announces Fourth Quarter and Full Year 2022 Financial Results
WINNIPEG, Manitoba, April 20, 2023 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (the “Company” or “Kane Biotech”), today announced its fourth quarter and full year 2022 financial results. Fourth Quarter Financial Highlights Total revenue for the three months ended December 31, 2022 was $691,654, an increase of 68% compared to $411,693 for the three months ended December 31, 2021. This increase is primarily attributable to increased pet retail sales, licensing revenue, and roya
- GlobeNewswire
Kane Biotech Announces Distribution Agreement with ProgenaCare Global for its coactiv+™ Antimicrobial Wound Gel
ProgenaCare to commercialize coactiv+™ Antimicrobial Wound Gel in the U.S. wound care marketWINNIPEG, Manitoba, April 20, 2023 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE OTCQB:KNBIF) (the “Company”, “Kane” or “Kane Biotech”) announced today that it has signed a distribution agreement with ProgenaCare Global LLC (“ProgenaCare”) for its coactiv+™ Antimicrobial Wound Gel in the United States wound care market. ProgenaCare will have exclusive distribution rights in the United States wound care
- GlobeNewswire
Kane Biotech Announces Additional coactiv+™ Animal Health Licensing Agreement
Skout’s Honor to license coactiv+™ in North American pet specialty markets.WINNIPEG, Manitoba, April 18, 2023 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE OTCQB:KNBIF) (the “Company”, “Kane” or “Kane Biotech”) announces that it has signed a licensing agreement with Skout’s Honor Pet Supply Company (“Skout’s Honor”) for its patented coactiv+™ technology in pet oral care applications. Skout’s Honor has been granted a ten-year license for the non-exclusive use of Kane’s coactiv+™ technology und
- GlobeNewswire
Kane Biotech to Release Fourth Quarter and Full Year 2022 Financial Results on April 20, 2023 – Conference Call to Follow
WINNIPEG, Manitoba, April 13, 2023 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (the “Company” or “Kane Biotech”), a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms, will announce its fourth quarter and full year 2022 financial results after market close on Thursday, April 20, 2023. Kane Biotech management will host a conference call at 4:30 p.m. ET to review the financial
- GlobeNewswire
Kane Biotech Clarifies Terms of Credit Facility
Not for distribution to U.S. news wire services or dissemination in the United States WINNIPEG, Manitoba, March 03, 2023 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (the “Company” or “Kane Biotech”) announces that, as previously announced by the Company in its March 1, 2023 press release, pursuant to the formal amending agreement (the “Amending Agreement”) with Pivot Financial I Limited Partnership (“Pivot”) dated March 2, 2023 amending the terms of the Company’s amended and
- GlobeNewswire
Kane Biotech Announces Amendment to its Credit Facility
Not for distribution to U.S. news wire services or dissemination in the United States WINNIPEG, Manitoba, March 02, 2023 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE; OTCQB:KNBIF) (the “Company” or “Kane Biotech”) today announced that it has entered into a formal amending agreement (the “Amending Agreement”) with Pivot Financial I Limited Partnership (“Pivot”), to amend the terms of the Company’s amended and restated credit agreement between Pivot and the Company dated August 31, 2021, as am
- GlobeNewswire
Kane Biotech Announces Proposed Amendments to its Credit Facility and Changes to its Board of Directors
Not for distribution to U.S. news wire services or dissemination in the United States WINNIPEG, Manitoba, March 01, 2023 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE; OTCQB:KNBIF) (the “Company” or “Kane Biotech”) today announced that Pivot Financial I Limited Partnership (“Pivot”) has agreed, in principle, to amend the terms of the Company’s amended and restated credit agreement between Pivot and the Company dated August 31, 2021, as amended (the “Credit Facility”), by, among other things,
- GlobeNewswire
Kane Biotech Announces Extension of Term of Credit Facility
Not for distribution to U.S. news wire services or dissemination in the United States WINNIPEG, Manitoba, Feb. 06, 2023 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (the “Company” or “Kane Biotech”) announces today that it has entered into an amending agreement with Pivot Financial I Limited Partnership (“Pivot”) to the amended and restated credit agreement between the Company and Pivot dated August 31, 2021, extending the maturity date of its credit facility from January 31, 2023 to Februa
- GlobeNewswire
Kane Biotech Announces First Distribution Agreement for its coactiv+™ Antimicrobial Hydrogel
Salud Pharma to launch product in Colombia, Panama, and Costa RicaWINNIPEG, Manitoba, Jan. 04, 2023 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE OTCQB:KNBIF) (the “Company” or “Kane Biotech”) announces today that it has recently signed a distribution agreement with Salud Pharma S.A. (“Salud Pharma”) for its coactiv+™ Antimicrobial Hydrogel wound care and DermaKB™ scalp care products. Once Kane obtains 510(k) approval from the FDA, Salud Pharma through its distribution partners will register
- GlobeNewswire
Kane Biotech Announces Loan Transaction
WINNIPEG, Manitoba, Dec. 29, 2022 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (the “Company” or “Kane Biotech”) today announces that it has reached an agreement to obtain loans (the “Loans”) in the aggregate amount of $2,000,000 from two lenders (the “Lenders”). The Loans will bear interest at 12% per annum and mature on March 31, 2024. As partial consideration for providing the Loans, the Lenders will be issued an aggregate of 4,705,882 common shares of the Company (the “Bon
- GlobeNewswire
Kane Biotech Announces Third Quarter 2022 Financial Results
Company Files First 510(k) Application in Wound CareWINNIPEG, Manitoba, Nov. 24, 2022 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (the “Company” or “Kane Biotech”) today announced its third quarter 2022 financial results. Financial Highlights: Total revenue for the three months ended September 30, 2022 was $571,686 an increase of 5% compared to $541,302 in the three months ended September 30, 2021. In the nine months ended September 30, 2022, total revenue increased by 65% to
- GlobeNewswire
Kane Biotech to Release Third Quarter 2022 Financial Results on November 24, 2022 – Conference Call to Follow
WINNIPEG, Manitoba, Nov. 17, 2022 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE; OTCQB:KNBIF) (the “Company” or “Kane Biotech”), a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms, will announce its third quarter 2022 financial results after market close on Thursday, November 24, 2022. Kane Biotech management will host a conference call at 4:30 p.m. ET to review the financial results and di
- GlobeNewswire
Kane Biotech Announces 510(k) Submission for its coactiv+™ Antimicrobial Hydrogel
WINNIPEG, Manitoba, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE OTCQB:KNBIF) (the “Company” or “Kane Biotech”) announces that it has recently submitted a 510(k) premarket notification, which has been received by The Center for Devices and Radiological Health (CDRH) of the U.S. Food and Drug Administration (“FDA”), for a new Wound Care coactiv+™ Antimicrobial Hydrogel. The Company’s device, which uses its patented coactiv+™ technology in a thermo-reversible gelling system, prov
- GlobeNewswire
Kane Biotech to Present at Symposium on Advanced Wound Care Fall Forum
Company presenting technologies for improving patient outcomes in wound careWINNIPEG, Manitoba, Oct. 13, 2022 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE OTCQB:KNBIF) (the “Company” or “Kane Biotech”) today announces that the Company will be presenting at the Symposium on Advanced Wound Care (SAWC) Fall forum. The conference will take place on October 13-16, 2022 in Las Vegas, Nevada and is intended to connect the entire wound care team fostering inclusivity, innovation and interdisciplinar
- GlobeNewswire
Kane Biotech Receives an Additional $425K USD of Funding for its DispersinB® Hydrogel from the United States Department of Defense
DispersinB® Hydrogel Clinical trials to commence in 2022WINNIPEG, Manitoba, Oct. 04, 2022 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE; OTCQB:KNBIF) (the “Company” or “Kane Biotech”) today announces that it has received an additional $425,000 USD of funding for its DispersinB Hydrogel® related to its Medical Technology Enterprise Consortium Research Project Award which was granted in 2020 and funded by the U.S. Department of Defense. This additional funding supplements the approximately $2.7
- GlobeNewswire
Kane Biotech Announces Second Quarter 2022 Financial Results
Significant Milestones AchievedWINNIPEG, Manitoba, Aug. 25, 2022 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (the “Company” or “Kane Biotech”) today announced its second quarter 2022 financial results. Second Quarter Financial Highlights: Total revenue for the three months ended June 30, 2022 was $839,579, an increase of 201% compared to $278,741 in the three months ended June 30, 2021.License revenue in the three months ended June 30, 2022 was $500,225, an increase of 1,295%
- GlobeNewswire
Kane Biotech to Release Second Quarter 2022 Financial Results on August 25, 2022 – Conference Call to Follow
WINNIPEG, Manitoba, Aug. 18, 2022 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (the “Company” or “Kane Biotech”), a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms, will announce its second quarter 2022 financial results after market close on Thursday, August 25, 2022. Kane Biotech management will host a conference call at 4:30 p.m. ET to review the financial results and di
- GlobeNewswire
Kane Biotech Announces Adoption of Amended and Restated Stock Option Plan and Performance and Restricted Share Unit Plan
Not for distribution to U.S. news wire services or dissemination in the United States WINNIPEG, Manitoba, June 30, 2022 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (the “Company” or “Kane Biotech”) announces that, following the approval of the shareholders of the Company (the “Shareholders”) at the annual general and special meeting of Shareholders held on May 26, 2022, the Company adopted the second amended and restated stock option plan of the Company and the amended and restated perform
- GlobeNewswire
Kane Biotech Announces Amended Credit Facility
WINNIPEG, Manitoba, June 15, 2022 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE; OTCQB:KNBIF), (the “Company” or “Kane Biotech”), today announces that it has further amended its credit agreement with Pivot Financial Inc. (“Pivot”) maturing August 31, 2022 (the “Amended Credit Facility”). The amendment dated June 13, 2022 extends the maturity to January 31, 2023 and increases the credit facility to $4 million with approximately $1.8 million of new capital having been provided. The increased cr
